CN115667269A - 含吡啶酮稠环类衍生物抑制剂、其制备方法和应用 - Google Patents

含吡啶酮稠环类衍生物抑制剂、其制备方法和应用 Download PDF

Info

Publication number
CN115667269A
CN115667269A CN202180035702.1A CN202180035702A CN115667269A CN 115667269 A CN115667269 A CN 115667269A CN 202180035702 A CN202180035702 A CN 202180035702A CN 115667269 A CN115667269 A CN 115667269A
Authority
CN
China
Prior art keywords
radical
alkyl
cyano
cycloalkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180035702.1A
Other languages
English (en)
Inventor
刘世强
黄胜爱
袁逸达
包如迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Shanghai Hansoh Biomedical Co Ltd
Original Assignee
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Shanghai Hansoh Biomedical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co Ltd filed Critical Jiangsu Hansoh Pharmaceutical Group Co Ltd
Publication of CN115667269A publication Critical patent/CN115667269A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种含吡啶酮稠环类衍生物抑制剂、其制备方法和应用。涉及通式(I)所示的化合物或其立体异构体、其制备方法及含有该化合物的药物组合物，及其作为Cap依赖的核酸内切酶抑制剂在治疗和/或预防由流感病毒引起的相关疾病中的应用。

Description

PCT国内申请，说明书已公开。

Claims (16)

  1. PCT国内申请，权利要求书已公开。
CN202180035702.1A 2020-06-12 2021-06-11 含吡啶酮稠环类衍生物抑制剂、其制备方法和应用 Pending CN115667269A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202010536663 2020-06-12
CN2020105366630 2020-06-12
CN202011240023 2020-11-09
CN2020112400231 2020-11-09
PCT/CN2021/099565 WO2021249522A1 (zh) 2020-06-12 2021-06-11 含吡啶酮稠环类衍生物抑制剂、其制备方法和应用

Publications (1)

Publication Number Publication Date
CN115667269A true CN115667269A (zh) 2023-01-31

Family

ID=78846902

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180035702.1A Pending CN115667269A (zh) 2020-06-12 2021-06-11 含吡啶酮稠环类衍生物抑制剂、其制备方法和应用

Country Status (3)

Country Link
CN (1) CN115667269A (zh)
TW (1) TW202146413A (zh)
WO (1) WO2021249522A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023222084A1 (zh) * 2022-05-20 2023-11-23 成都地奥九泓制药厂 苯并咪唑或氮杂苯并咪唑类化合物、其制备方法及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102482219A (zh) * 2009-03-26 2012-05-30 盐野义制药株式会社 吡喃酮和吡啶酮衍生物的制备方法
CN102803260A (zh) * 2009-06-15 2012-11-28 盐野义制药株式会社 被取代的多环性氨基甲酰基吡啶酮衍生物
CN103228653A (zh) * 2010-09-24 2013-07-31 盐野义制药株式会社 被取代的多环性氨基甲酰基吡啶酮衍生物的前药
WO2020004443A1 (ja) * 2018-06-27 2020-01-02 国立大学法人北海道大学 多環性カルバモイルピリドン誘導体を含有するアレナウイルス増殖阻害剤
WO2020075080A1 (en) * 2018-10-10 2020-04-16 Janssen Biopharma, Inc. Macrocyclic flu endonuclease inhibitors
WO2021191872A1 (en) * 2020-03-26 2021-09-30 Janssen Biopharma, Inc. Heteroaryl-substituted macrocyclic flu endonuclease inhibitors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102482219A (zh) * 2009-03-26 2012-05-30 盐野义制药株式会社 吡喃酮和吡啶酮衍生物的制备方法
CN102803260A (zh) * 2009-06-15 2012-11-28 盐野义制药株式会社 被取代的多环性氨基甲酰基吡啶酮衍生物
CN103228653A (zh) * 2010-09-24 2013-07-31 盐野义制药株式会社 被取代的多环性氨基甲酰基吡啶酮衍生物的前药
WO2020004443A1 (ja) * 2018-06-27 2020-01-02 国立大学法人北海道大学 多環性カルバモイルピリドン誘導体を含有するアレナウイルス増殖阻害剤
WO2020075080A1 (en) * 2018-10-10 2020-04-16 Janssen Biopharma, Inc. Macrocyclic flu endonuclease inhibitors
WO2021191872A1 (en) * 2020-03-26 2021-09-30 Janssen Biopharma, Inc. Heteroaryl-substituted macrocyclic flu endonuclease inhibitors

Also Published As

Publication number Publication date
TW202146413A (zh) 2021-12-16
WO2021249522A1 (zh) 2021-12-16

Similar Documents

Publication Publication Date Title
US10968221B2 (en) Substituted [1,2,4]triazolo[1,5-a]pyrazines as LSD1 inhibitors
US10138249B2 (en) Triazolopyridines and triazolopyrazines as LSD1 inhibitors
EP3105219B9 (en) Cyclopropylamines as lsd1 inhibitors
TWI652269B (zh) 氮雜吡啶酮化合物及其用途
CA3020275A1 (en) Mdm2 protein degraders
US20170369497A1 (en) Imidazopyrazines as lsd1 inhibitors
WO2015123437A1 (en) Cyclopropylamines as lsd1 inhibitors
EP3426244B1 (en) 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
EP2976340B1 (en) Cycloalkyl nitrile pyrazolo pyridones as janus kinase inhibitors
CN112778330A (zh) 含吡啶酮多环类衍生物抑制剂、其制备方法和应用
WO2010037210A1 (en) Viral polymerase inhibitors
AU2013267555A1 (en) Chromane compounds
CN115667269A (zh) 含吡啶酮稠环类衍生物抑制剂、其制备方法和应用
CN109265471B (zh) Fxr受体激动剂
KR20170005865A (ko) Ｎａｍｐｔ 억제제 및 방법
WO2021083246A1 (zh) 四元环类衍生物调节剂、其制备方法和应用
JP4458745B2 (ja) パピローマウイルス阻害剤
CN107849014B (zh) 一种联苯衍生物及其制备方法和在医药上的用途
CN117683042A (zh) 稠合四环类化合物、其制备方法及其在医药上的应用
GB2448808A (en) Substituted imidazo[1,2-a]pyridines and their use as agonists at GABA-A receptors for treating or preventing neurological or psychiatric disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40079963

Country of ref document: HK